DaVita Inc. (NYSE:DVA) Shares Acquired by Glenmede Trust Co. NA

Glenmede Trust Co. NA increased its position in DaVita Inc. (NYSE:DVA) by 731.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 123,269 shares of the company’s stock after purchasing an additional 108,446 shares during the period. Glenmede Trust Co. NA’s holdings in DaVita were worth $20,207,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. raised its position in shares of DaVita by 29.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock valued at $6,942,000 after acquiring an additional 11,454 shares in the last quarter. Comerica Bank lifted its stake in shares of DaVita by 41.4% in the 1st quarter. Comerica Bank now owns 34,431 shares of the company’s stock worth $4,753,000 after acquiring an additional 10,074 shares during the period. Quest Partners LLC bought a new position in DaVita during the 3rd quarter valued at $669,000. MBB Public Markets I LLC acquired a new position in DaVita during the second quarter worth about $582,000. Finally, Chase Investment Counsel Corp grew its stake in shares of DaVita by 56.3% in the 3rd quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock worth $5,423,000 after purchasing an additional 11,912 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Stock Down 1.3 %

DaVita stock opened at $165.71 on Thursday. The company has a market capitalization of $13.59 billion, a P/E ratio of 17.88, a P/E/G ratio of 0.94 and a beta of 0.89. DaVita Inc. has a 1-year low of $98.26 and a 1-year high of $169.51. The firm’s fifty day simple moving average is $158.42 and its 200-day simple moving average is $148.87. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the previous year, the company earned $2.85 EPS. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. Sell-side analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of recent analyst reports. Truist Financial boosted their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. UBS Group upped their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Bank of America increased their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Finally, Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $161.80.

Insider Activity

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is currently owned by company insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.